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Summary
Familial Mediterranean fever (FMF) is a recessive dis-
order characterized by episodes of fever with serositis
or synovitis. The FMF gene (MEFV) was cloned recently,
and four missense mutations were identified. Here we
present data from non-Ashkenazi Jewish and Arab pa-
tients in whom we had not originally found mutations
and from a new, more ethnically diverse panel. Among
90 symptomatic mutation-positive individuals, 11 mu-
tations accounted for 79% of carrier chromosomes. Of
the two mutations that are novel, one alters the same
residue (680) as a previously known mutation, and the
other (P369S) is located in exon 3. Consistent with an-
other recent report, the E148Q mutation was observed
in patients of several ethnicities and on multiple micro-
satellite haplotypes, but haplotype data indicate an an-
cestral relationships between non-Jewish Italian and
Ashkenazi Jewish patients with FMF and other affected
populations. Among ∼200 anonymous Ashkenazi Jew-
ish DNA samples, the MEFV carrier frequency was
21%, with E148Q the most common mutation. Several
lines of evidence indicate reduced penetrance among
Ashkenazi Jews, especially for E148Q, P369S, and
K695R. Nevertheless, E148Q helps account for recessive
inheritance in an Ashkenazi family previously reported
as an unusual case of dominantly inherited FMF. The
presence of three frequent MEFV mutations in multiple
Mediterranean populations strongly suggests a hetero-
zygote advantage in this geographic region.
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Introduction
Familial Mediterranean fever (FMF; MIM 249100) is
a recessively inherited disorder characterized by
acute, self-limited attacks of fever and dramatic but
unexplained migration of granulocytes into the serosal
or synovial spaces (reviewed in Samuels et al. 1998).
Some patients also develop systemic amyloidosis because
of the widespread tissue deposition of a product of the
acute phase reactant serum amyloid A, most notably in
the kidneys. Recently, the gene causing FMF (designated
“MEFV”) was identified on chromosome 16p13.3 by
positional cloning (French FMF Consortium 1997; In-
ternational FMF Consortium 1997). It encodes a novel
protein, variously called “pyrin” or “marenostrin,” that
exhibits homology to a number of nuclear factors and
is expressed predominantly in granulocytes. On the basis
of the FMF phenotype, pyrin is likely to be a negative
regulator of granulocyte-mediated inflammation. FMF
is the prototype for several hereditary periodic fever syn-
dromes (reviewed in Centola et al. 1998; Kastner 1998),
including the recessively inherited hyperimmunoglobu-
linemia D with periodic fever syndrome (MIM 260920;
also known as “Dutch-type periodic fever”) and the
dominantly inherited familial Hibernian fever (MIM
142680) and familial periodic fever, which were recently
mapped to chromosome 12p13 (McDermott et al. 1998;
Mulley et al. 1998).
Although FMF has been reported in many different
countries, most large clinical series involve four Medi-
terranean populations: non-Ashkenazi Jews, Armenians,
Arabs, and Turks. Carrier frequencies, when they have
been estimated in these ethnic groups, are very high.
Among various non-Ashkenazi North African Jewish
populations, the carrier frequency has been estimated as
1/5–1/10 (Daniels et al. 1995; Yuval et al. 1995),
whereas among Armenians in Los Angeles it is ∼1/7
(Rogers et al. 1989). Such high frequencies in several
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geographically related populations suggest that carriers
of pyrin mutations might have a selective advantage,
possibly because of heightened resistance to a pathogen
endemic to the eastern Mediterranean.
The cloning ofMEFV immediately broadened our un-
derstanding of FMF population genetics. Four missense
mutations (M680I, M694V, M694I, and V726A), clus-
tered within 46 amino acids of a predicted 781–amino
acid protein, were responsible for a large percentage of
mutations in the two initial study panels of families
(French FMF Consortium 1997; International FMF
Consortium 1997). Two of these mutations,M694V and
V726A, are likely to date back at least to biblical times,
because they were seen in association with specific mi-
crosatellite haplotypes in populations that have been
separated for many centuries (International FMF Con-
sortium 1997). Moreover, four different microsatellite
haplotypes bearing the M694V mutation demonstrated
convergence of single nucleotide–polymorphism (SNP)
haplotypes within MEFV. In the case of the North Af-
rican Jewish population, 83%–93% of FMF carrier
chromosomes bore the M694V mutation in association
with one microsatellite haplotype, strongly supporting
genetic drift as an explanation for the high gene fre-
quency in this ethnic group.
Since the cloning of MEFV, we and others have con-
tinued to screen for disease-associated mutations. Our
goals have been to find mutations in the small number
of individuals from our original study panel in whom
they had not already been found and to assess the spec-
trum of mutations in a more ethnically diverse sample.
It was unclear whether the four originally described mu-
tations would account for a large percentage of new
cases, because our initial panel of families was skewed
with regard to both their ethnic background (predom-
inantly non-Ashkenazi Jewish) and their disease severity
(families with mild disease generally were not included).
In an analysis of American periodic fever referrals (Sa-
muels et al. 1998), we reported four previously undes-
cribed MEFV mutations (E148Q, K695R, A744S, and
R761H). A French group (Bernot et al. 1998) indepen-
dently presented these same new mutations and four
others (E167D, T267I, F479L, and I692del). Two ad-
ditional mutations (T681I and M694del) were recently
reported by an English group (Booth et al. 1998). The
present study is a comprehensive analysis of patients and
families from Israel, the United States, and Europe. In
addition to identifying two novelMEFV mutations, this
work presents the broadest FMF mutational screening
to date in a large, ethnically diverse study population.
Overall, the second most common mutation in the
recent American and French series was E148Q, occur-
ring in all the major affected ethnic groups. Haplotype
analysis of modern-day chromosomes bearing this mu-
tation can provide evidence with respect to whether it
is present on several independent lineages of carrier chro-
mosomes, and is therefore a recurring mutation, or on
a single common carrier chromosome, and is therefore
caused by a single mutational event. On the basis of
microsatellites flankingMEFV, Bernot et al. (1998) con-
cluded that the former possibility is most likely. How-
ever, it should be noted that intragenic SNP analysis of
four apparently distinct microsatellite haplotypes bear-
ing another mutation (M694V) strongly suggests that
they have a common, but relatively ancient, origin (In-
ternational FMF Consortium 1997); we also found SNP
convergence for two microsatellite haplotypes bearing
M680I. The present study revisits the genesis of the
E148Q mutation, on the basis of similar intragenic SNP
haplotype analyses.
We were also interested in exploring the origins and
frequency of mutations in populations in which these
have not been previously examined. One such group is
the Ashkenazi Jewish population. Previous data on the
prevalence of FMF among Ashkenazi Jews are contra-
dictory. Although the first recognizable case description
of FMF involved an Ashkenazi Jewish girl (Janeway and
Mosenthal 1908) and one of the first large American
series of patients (under the name “familial paroxysmal
polyserositis”) was predominantly Ashkenazi Jewish
(Siegal 1964), population-based studies from Israel have
indicated a comparatively low carrier frequency of 1/
135 (Yuval et al. 1995) among the Ashkenazim. If true,
lower carrier frequencies in the Ashkenazi population
could be attributable either to genetic drift or to the
absence of a putative heterozygote advantage. In con-
trast, by means of a method based on the frequency of
FMF among the first cousins of FMF probands, Daniels
et al. (1995) estimated a carrier frequency of 1/11.4.
These latter results, although determined on the basis of
a small sample, suggest underascertainment of FMF
among the Ashkenazi population. Consistent with such
a possibility, FMF in Ashkenazi Jews is generally less
severe than among Sephardic Jews, with a markedly
lower rate of amyloidosis (Pras et al. 1982). Conceivably,
this could be the result of differences in MEFV muta-
tions, modifying genes, or nongenetic environmental ef-
fects. The present study provided an opportunity to ex-
amine more directly the frequency, origin, and
penetrance of MEFV mutations in this population.
We also were able to obtain DNA for mutational anal-
ysis of an Israeli family of Ashkenazi ancestry that had
previously been reported (Yuval et al. 1995) as probably
exhibiting dominant inheritance of FMF. This was
clearly of interest, because segregation analysis (Sohar
et al. 1961) and initial mutation studies (French FMF
Consortium 1997; International FMF Consortium
1997) support a recessive mode of inheritance. Other
cases of possible dominant inheritance of FMF have been
explained as pseudodominance because of the high car-
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rier frequency for FMF in Mediterranean populations.
The family studied here was not thought to be attrib-
utable to this phenomenon because four-generation in-
heritance of FMF was thought to be highly improbable
in the face of a calculated low Ashkenazi gene frequency.
Here we were able to test directly the mutational status
of affected members of this family, as well as to deter-
mine more accurately the gene frequency that had served
as the basis for the assertion of dominant inheritance.
Finally, the status of FMF among Mediterranean pop-
ulations other than Jews, Arabs, Turks, and Armenians
has been unclear. The only relevant published data are
found in a small number of case reports, the most nu-
merous of which concern Italians or Italian-Americans.
In the past 30 years, there have been six such reports of
so-called Italian FMF (Reich and Franklin 1970; Secchi
et al. 1981; Passiu et al. 1984; Gentiloni et al. 1992;
Marinone et al. 1992; Breda et al. 1998); all the patients
were from southern Italy or Sicily. In one case, intestinal
amyloidosis was documented (Reich and Franklin 1970)
but occurred relatively late in life. There are also two
reports of patients from Malta with FMF (Siegal et al.
1964; Rosenstein and Kramer 1994), an island lying
south of Sicily in the Mediterranean. Nevertheless, pa-
tients of Italian ancestry with periodic fever and serositis
were the third most common ethnic group (after Ar-
menians and Ashkenazi Jews) among American patients
(Samuels et al. 1998), and we have received additional
Italian referrals from Sicily and Belgium.With the largest
single experience with this ethnic group to date, we have
investigated the spectrum of MEFV mutations and car-
rier haplotypes in Italian patients with FMF.
Families and Methods
Families and DNA Specimens
The present study included several Israeli families
from our previous linkage and positional cloning proj-
ects (Balow et al. 1997; International FMF Consortium
1997). Seven of the 61 families from these earlier studies
were chosen because we had not identified both MEFV
mutations in affected individuals, whereas other families
with known mutations were chosen for intragenic or
extragenic haplotype analysis. All these families had
been ascertained and sampled at the Chaim Sheba Med-
ical Center in Tel-Hashomer, Israel, as described else-
where (International FMF Consortium 1997). The di-
agnosis of FMF in all these families was made according
to established clinical criteria (Sohar et al. 1967; Livneh
et al. 1997). After obtaining informed consent, we col-
lected blood samples from available family members.
DNA was extracted from whole blood or from Epstein-
Barr virus–transformed lymphocytes by standard tech-
niques. Overall, we included nine Israeli families of non-
Ashkenazi and two of Ashkenazi Jewish ancestry and
five Israeli families of Arab/Druze ancestry.
Subsequent to the identification of MEFV, we per-
formed mutational analysis on DNA samples derived
from a total of 274 additional individuals. These in-
cluded patients meeting clinical criteria for FMF who
desired genetic confirmation of the diagnosis; individuals
with unexplained fever, abdominal pain, or arthritis
atypical of FMF who were seeking a diagnosis; and sev-
eral asymptomatic relatives of patients. A total of 82
individuals were seen at the Clinical Center of the Na-
tional Institutes of Health (NIH), 145 samples were sent
from other sites in the United States, and an additional
47 samples were sent from outside the United States.
The latter included samples from two Italian families,
one living in Sicily and the other in Belgium. After sub-
jects gave written informed consent, 5 ml of blood was
drawn into tubes containing EDTA; samples from out-
side the NIH were express-shipped at ambient temper-
ature. Genomic DNA was extracted from whole blood
by means of a commercially available kit (Puregene,
Gentra Systems).
Various control DNA samples were used in these stud-
ies. A total of 60 were from NIH Blood Bank donors,
and 51 anonymous white controls were obtained at New
York University. An additional 93 samples were from
well-characterized Israeli FMF families; 12 were non-
carriers and 81 were carriers, as determined by haplo-
type analysis.
In addition, MEFV mutational surveys were per-
formed on a total of 213 anonymous American Ash-
kenazi Jewish DNA samples obtained from couples un-
dergoing carrier screening for cystic fibrosis, Gaucher
disease, and Tay-Sachs disease (Kronn et al. 1998). The
frequencies of mutations in CFTR, glucocerebrocidase
(Gaucher disease), hexosaminidase A (Tay-Sachs dis-
ease), N-aspartoacylase (Canavan disease), BRCA1,
BRCA2, and APC observed in this population are sim-
ilar to those observed in other series of Ashkenazi
samples.
Microsatellite Analysis
Genotyping for D16S3370, D16S2617, D16S3373,
D16S3275, and D16S3376 was performed as described
by Balow et al. (1997). Genotyping for D16S3403,
D16S3404, and D16S3405 (International FMF Con-
sortium 1997) was performed by use of oligonucleotide
primers and PCR conditions available through the Ge-
nome Database. Microsatellite haplotypes were con-
structed so as to minimize the number of intrafamilial
recombinations.
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Genomic DNA Sequencing
We amplified individual MEFV exons and flanking
intronic sequences from genomic DNA by using M13-
tailed oligonucleotide primers and PCR conditions, as
described elsewhere (International FMF Consortium
1997), except as follows. In the present study, exon 2
was amplified in two overlapping PCR fragments. The
forward and reverse oligonucleotide primers used to am-
plify the 5′ end of exon 2 were 5′-ATCATTTTGCATCT-
GGTTGTCCTTCC-3′ and 5′-TCCCCTGTAGAAAT-
GGTGACCTCAAG-3′, respectively. The forward and
reverse primers used to amplify the 3′ end of exon 2 were
5′-GGCCGGGAGGGGGCTGTCGAGGAAGC-3′ and
5′-TCGTGCCCGGCCAGCCATTCTTTCTC-3′, respec-
tively. Exons 8 and 9 were amplified separately in the
present study. The forward primer for exon 8 was 5′-
GCATGCTCACTTCCTCCCTA-3′; and the reverse
primer was 5′-CTTTGCTCCAGGTGTTTGGT-3′. The
forward primer for exon 9 was 5′-TTAGACCACAGT-
CCCCAACA-3′; and the reverse primer was 5′-CAGG-
AAACAGGGACAGGGTA-3′.
Mutation detection was performed by fluorescent se-
quencing with dye-primer chemistry, as described else-
where (International FMF Consortium 1997). Sequenc-
ing reactions were run on an ABI 377 automated
sequencer, and data were analyzed with SEQUENCHER
3.0 (Gene Codes).
Amplification-Refractory Mutation Screening (ARMS)
We performed ARMS assays by amplifying 100 ng
genomic DNA in a total volume of 25 ml, with 1 pmol
of each primer and 0.2 mM dNTPs (Gibco BRL), in 1#
PCR buffer and 0.04 U AmpliTaq Gold (Perkin Elmer).
The PCR amplification was performed under the fol-
lowing conditions: 94C for 10 min, followed by 35
cycles of 94C for 10 s, 60C for 10 s, and 72C for 30
s, with a final extension time of 10 min at 72C. The
annealing temperatures for the M694V and M694I as-
says were 55C and 50C, respectively. The amplified
products were separated by electrophoresis on a 1%
agarose gel and stained with ethidium bromide.
Restriction Analysis of PCR Products from Genomic
DNA
Restriction analysis was performed with the following
steps: 50–100 ng genomic DNA in a total volume of 10
ml were amplified in 1.5 mmol MgCl2 PCR buffer and
0.04 U AmpliTaq Gold. PCR began with 95C for 10
min, followed by 35 cycles of 95C for 30 s, 55C for
30 s, and 72C for 30 s, with the final extension at 72C
for 10 min. The annealing temperature for the P369S
amplification was 60C. The amplified products were
digested for 2 h with 10 U of the appropriate restric-
tion enzymes (BstNI, AluI, or HinfI). Positive and neg-
ative controls were included in each run. The samples
were loaded on 4%–20% polyacrylamide gels (Novex)
and stained with ethidium bromide.
SNP Analysis of FMF Carrier Chromosomes
MEFV intragenic SNP haplotypes were determined by
DNA sequencing. In addition to known sites of muta-
tions, 11 intragenic SNPs were evaluated, as described
elsewhere (International FMF Consortium 1997). Ac-
cording to our previous nomenclature, exonic SNPswere
designated by “x,” and intronic SNPs by “i,” with
“x2.1” indicating the first SNP in exon 2. In order from
telomere to centromere, including five known sites of
mutations, the SNPs studied in this report were: V726A
(T/C, nt 2177), M694V (A/G, nt 2080), M680I (G/C/
A, nt 2040), x9.1 (A/G, nt 1764), i6.1 (C/T, nt
161095), x5.3 (C/T, nt 1530), x5.2 (A/G, nt 1428),
x5.1 (A/G, nt 1422), i4.1 (A/G, nt 135643), P369S
(C/T, nt 1105), x3.1 (C/T, nt 942), x2.4 (A/G, nt 605),
x2.3 (A/C, nt 495), E148Q (G/C, nt 442), x2.2 (A/G,
nt 414), and x2.1 (C/T, nt 306). Underlined sites are
locations of mutations, with mutant alleles in boldface
type.
Results
MEFV Mutational Survey
Since the initial identification of MEFV, we have used
automated sequencing of PCR-amplified genomic DNA
to screen for mutations. We have concentrated on new
referrals and the small percentage of our original study
panel, mostly patients of Arab or Druze ancestry, in
whom we had not found any of the then four known
MEFV mutations. After sequencing the entire coding
region and splice junctions in several patients of Arab/
Druze ancestry, we identified two disease-associatedmis-
sense mutations in exon 2. These two mutations, which
result in the substitution of glutamine for glutamic acid
at codon 148 (E148Q) and of aspartic acid for glutamic
acid at codon 167 (E167D), are depicted in figure 1A
and B. Sequencing of the entire MEFV coding region
and haplotype analysis in a family segregating E167D
indicated that this mutation can exist as the only coding
abnormality on a carrier chromosome, whereas a similar
analysis of E148Q demonstrated that this substitution
can occur either as the sole amino acid change on a
carrier chromosome or as a complex allele with one of
two other mutations (discussed below). Restriction en-
donuclease (E148Q) or ARMS (E167D) assays (fig. 1,
bottom panels; table 1) permitted rapid screening of a
panel of control chromosomes; E167D was not found
in any of 100 control chromosomes, whereas E148Q
was found in 1 of 246 controls. Bernot et al. (1998) also
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Figure 1 DNA sequence electropherograms and rapid-screening assays for seven missense mutations identified in the present survey. The
P369S and M680I mutations are novel. The upper three panels depict individuals who were normal, heterozygous, and, where available,
homozygous for each of these sites. The downward arrow indicates the point of the single-base mutation. The lower panels depict rapid-
screening assays that were developed for each of the mutations. ARMS assays were developed for E167D, K695R, A744S, and R761H. For
these assays, the upper photograph in the lower panel represents the product of the mutant-specific primer pair, and the lower photograph
represents the product of the wild-type primer pair. Restriction endonuclease analyses of PCR products were used for E148Q, P369S, and
M680I. “W” denotes wild-type, “C” denotes the carrier for the mutation, “H” denotes homozygous for the mutation, and “D” denotes the
distilled-water control.
recently reported E148Q in their Druze population and
found E167D in an Armenian patient.
Mutational screening was also performed on a set of
1200 DNA samples from patients with periodic fevers.
The clinical spectrum ranged from patients with classic
histories of FMF to those with unexplained and some-
times very atypical constellations of symptoms. Clinical
details of 100 of the referrals from the United States (47
with identifiable MEFV mutations) are presented else-
where (Samuels et al. 1998). Because all four of the
mutations initially described in MEFV were in exon 10,
our mutational screen included sequencing of the coding
region of this exon in its entirety for all 274 individuals.
In addition to the initially described mutations, four
other missense substitutions in this exon were identified
among these patients (2040GrA, M680I, fig. 1D;
2084ArG, K695R, fig. 1E; 2230GrT, A744S, fig. 1F;
and 2282GrA, R761H, fig. 1G). One of these muta-
tions, 2040GrA, is novel and is the second reported
single-nucleotide alteration leading to an M680I sub-
stitution (the first being a GrC transversion at the same
position). For a R761H homozygote, sequencing of the
entire coding region and splice junctions failed to iden-
tify any other sequence changes. For M680I
954 Am. J. Hum. Genet. 64:949–962, 1999
Table 1
PCR Primers Used in Mutation Assays
Mutation Assay/Primer Type Primer
442GrC (E148Q) BstNI Digest:
Forward 5′-GCCTGAAGACTCCAGACCACCCCG- 3′
Reverse 5′-AGGCCCTCCGAGGCCTTCTCTCTG-3′
501GrC (E167D) ARMS:
Mutant 5′-GGGCTCCGGGTCCGAGGCTTGCCCTGCGCGTCCAGGCCG-3′
Normal 5′-GGGCTCCGGGTCCGAGGCTTGCCCTGCGCGTCCAGGCCC-3′
Common 5′-TATTCCACACAAGAAAACGGCACAGATGATTCCGCAGCG-3′
1105CrT (P369S) AluI Digest:
Forward 5′-TCCCCGAGGCAGTTTCTGGGCACC-3′
Reverse 5′-TGGACCTGCTTCAGGTGGCGCTTAC-3′
2040GrA (M680I) HinfI Digest:
Forward 5′-GAGGTTGGAGACAAGACAGCATGG-3′
Reverse 5′-TCGGGGGAACGCTGGACGCCTGGTACTCATTTTCCT-3′
2084ArG (K695R) ARMS:
Mutant 5′-TCGGGGGAACGCTGGACGCCTGGTACTCATTTTCCC-3′
Normal 5′-TCGGGGGAACGCTGGACGCCTGGTACTCATTTTCCT-3′
Common 5′-TTAGACTTGGAAACAAGTGGGAGAGGCTGC-3′
2230GrT (A744S) ARMS:
Mutant 5′-GAAGATAGGTTGAAGGGGCCCAGAGAAAGAGCAGCTGAA-3′
Normal 5′-GAAGATAGGTTGAAGGGGCCCAGAGAAAGAGCAGCTGAC-3′
Common 5′-TGGAGGTTGGAGACAAGACAGCATGGATCC-3′
2282GrA (R761H) ARMS:
Mutant 5′-ACAGATAGTCAGAGGAGCTGTGTTCTTCCCTCCATCTT-3′
Normal 5′-ACAGATAGTCAGAGGAGCTGTGTTCTTCCCTCCATCTC-3′
Common 5′-ACCCGCCTGCTAATAAAGGAGCCTCCCAAGCG-3′
(2040GrA), K695R, and A744S, we have not yet en-
countered a homozygous patient; analysis of coding and
splice sequences in patients harboring these latter mu-
tations revealed single additional heterozygous muta-
tions, presumably on the opposite parental chromosome.
Using restriction endonuclease and ARMS screening as-
says (fig. 1, bottom panels; table 1), we detected none
of these substitutions in control panels comprising NIH
Blood Bank volunteer samples or noncarrier chromo-
somes from FMF families.
Finally, in one of the Ashkenazi Jewish patients who
was homozygous for the E148Q mutation, sequencing
of entire coding region demonstrated that this individual
was heterozygous for a novel CrT transition at nt 1105
(P369S, fig. 1C). By using an AluI restriction endonu-
clease assay (fig. 1 and table 1), we subsequently iden-
tified P369S with E148Q in a second Ashkenazi Jewish
patient and without E148Q in three other patients (two
of whom had no known Jewish ancestry) but in only 1
of 222 control chromosomes.
Table 2 summarizes the frequencies of the various mu-
tations identified in the panel of 274 referrals from the
United States, Europe, and Israel. Screening consisted of
the sequencing of the entire coding region of exon 10,
plus ARMS/restriction endonuclease assays for E148Q,
E167D, and P369S. When possible, the phase of com-
plex alleles was assigned by genotyping parents or off-
spring. Consistent with the clinical heterogeneity of this
cohort, only 90 unrelated individuals had at least one
demonstrable mutation in MEFV. Of 180 carrier chro-
mosomes in these individuals, we could account for mu-
tations in 142 (79%). In contrast to the North African
Jewish population, in which 93% of carrier chromo-
somes bore M694V (International FMF Consortium
1997), only 27% of chromosomes (48 of 180) from the
present ethnically diverse cohort had this mutation.
When carrier chromosomes bearing mutations alone or
in combination were tabulated, V726A was the second
most common mutation (36 [20%] of 180), followed by
E148Q (26 [14%] of 180). It is also noteworthy that
patients of Ashkenazi Jewish and Italian ancestry ac-
counted for 20% and 16%, respectively, of the muta-
tion-positive referrals.
Origins of E148Q-Bearing Chromosomes
Previously published microsatellite and SNP haplo-
type data suggest that most M694V and V726A alleles
are descended from two ancestral chromosomes (French
FMF Consortium 1997; International FMF Consortium
1997). We therefore asked whether there is also such a
relationship among E148Q chromosomes, because, like
M694V and V726A, this mutation is prevalent and cuts
across ethnic boundaries. Table 3 presents microsatellite
and SNP haplotypes deduced for five carrier chromo-
somes with only the E148Q mutation. Consistent with
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Table 2
Distribution of MEFV Mutations among New Referrals, by Ethnic Group
NO. OF CHROMOSOMES WITH MUTATION
ETHNIC GROUPa E148Q E167D P369S M680Ib M680Ic M694V M694I K695R V726A A744S R761H 148/369 148/726 Total
Armenian (18) 4 1 1 6 0 11 0 0 5 0 2 0 0 30
Ashkenazi (18) 3 0 1 0 0 3 0 2 13 1 0 2 4 29
Italian (14) 7 0 0 1 1 6 1 0 2 0 1 0 1 20
Arab (14) 2 0 0 1 0 8 5 0 8 1 0 0 0 25
NAJ (9) 1 0 0 0 0 10 0 0 1 0 0 0 0 12
Turkish (8) 2 0 0 5 0 7 1 0 1 0 0 0 0 16
Spanish/Cuban (2) 0 0 0 0 0 2 0 0 0 0 0 0 0 2
Greek (1) 0 0 0 0 0 1 0 0 0 0 0 0 0 1
Iranian (1) 0 0 0 0 0 0 0 0 0 0 2 0 0 2
Other (5) 0 0 2 0 0 0 0 2 1 0 0 0 0 5
Total (90) 19 1 4 13 1 48 7 4 31 2 5 2 5 142
NOTE.—The T681I, I692del, and M694del mutations were not found in this set of patients.
a NAJ  non-Ashkenazi Jewish; numbers in parentheses represent numbers of unrelated patients.
b 2040GrC.
c 2040GrA.
recently published microsatellite data of Bernot et al.
(1998), multiple microsatellite haplotypes were discern-
ible. However, when these five carrier chromosomes
were typed for sites of known mutations and 11 intra-
genic SNPs (International FMF Consortium 1997), we
found that, despite the fact that there were four different
SNP motifs on the 3′ end of the gene, all these haplotypes
converged to G . . C . . C . . A . . T for the SNPs within
exon 2 (x2.4, x2.3, E148Q, x2.2, and x2.1). Against
the possibility that this might simply reflect a limited
degree of polymorphism for these SNPs, the frequencies
of the aforementioned alleles in a panel of 24 normal
chromosomes of Jewish ancestry were 62.5% G at x2.4,
54% C at x2.3, 50% A at x2.2, and 50% T at x2.1
(International FMF Consortium 1997).
Table 3 also compares haplotypes of chromosomes
bearing the complex E148Q-V726A carrier chromo-
some to those bearing these mutations individually.
Chromosomes with V726A alone and those with the
complex allele share microsatellite genotypes 3′ (telo-
meric) ofMEFV, but diverge 5′ (centromeric) of the gene,
suggesting that the complex allele is the result of recom-
bination. Moreover, E148Q-V726A chromosomes share
the C . . A . . G . . G . . T . . C . . G . . A . . G . . C
. . T haplotype at the 3′ end of MEFV, with the SNP
haplotype found in all V726A chromosomes. This sug-
gests that the recombination giving rise to the complex
allele may have occurred within MEFV. SNP data on
the 5′ end of E148Q-V726A chromosomes are consistent
with the common founder for all E148Q-bearing chro-
mosomes, although the precise location of the putative
intragenic recombination event would depend on the
SNP haplotype of the ancestral E148Q-bearing chro-
mosome that participated in this process.
Although the P369S mutation has been observedwith-
out E148Q in four individual samples, family data are
not yet available to permit a haplotype comparison of
chromosomes bearing P369S alone with those bearing
the P369S-E148Q complex allele. However, intragenic
SNP haplotype analysis of one Ashkenazi Jewish family
segregating the complex allele demonstrated the con-
served G . . C . . C . . A . . T motif in exon 2 of the
complex chromosome and of a chromosome bearing
E148Q alone, and heterozygosity at the exon 3 SNP in
the one individual who was heterozygous for E148Q
and E148Q-P369S.
FMF in the Ashkenazi Jewish Population
Because Ashkenazi Jewish patients with FMF repre-
sented a substantial percentage of the new referrals (table
2) and because FMF is thought to be relatively uncom-
mon in this population, it was of interest to determine
experimentally the frequencies of known MEFV muta-
tions among the Ashkenazim. Table 4 shows the results
of these studies in a cohort of Ashkenazi Jews under-
going carrier screening for other genetic disorders at the
New York University Medical Center. Although it was
not possible to contact members of this panel to inquire
about symptoms of FMF, none of these individuals noted
such complaints on a questionnaire administered at the
time blood samples were obtained. The overall carrier
frequency calculated from mutation frequencies was
21%, more than twice the 9% estimated from the fre-
quency of FMF in the first cousins of affected probands
(Daniels et al. 1995) and more than 25 # a recent es-
timate calculated on the basis of total numbers of Ash-
kenazi patients with FMF in Israel (Yuval et al. 1995).
Approximately one-half of the carrier chromosomes
we observed were attributable to E148Q, with P369S
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Table 3
Microsatellite and Intragenic SNP Haplotypes of FMF Carrier Chromosomes
INDIVIDUALa MUTATION
ALLELE SIZEb
(BP)
INTRAGENICc
(3′r 5′)
ALLELE SIZEb
(BP)
S3405 S3404 S3370 S2617 S3373 S3275 S3376
144-01A (Dr) E148Q 165 114 149 110 TAGGTTAGACCGCCAT 185 190 221
S.T. (AJ) E148Q 185 122 141 110 TAGACTAGAC GCCATCT 185 192 215
S.T. (AJ) E148Q-P369S 193 98 141 113 TAGACTAGAT GCCATCT 187 190 209
43-02B (AJ) E148Q 165 118 149 110 TAGGTCGAGCTGCCAT 185/187 194 205
146-07A (Arab) E148Q 165 110 141 101 TAGGCCGAGCTGCCAT 187 194 223
Sicilian E148Q 165 118 141 101 TAGGCCGAGCTGCCAT 187 194 217/219
43-02A (AJ) V726A-E148Q 165 110 149 107 CAGGTCGAGCTGCCAT 185/187 186 215
76-06 (Dr) V726A-E148Q 165 110 149 107 CAGGTCGAGCTGCCAT 187 186 201
33-02A (IrJ) V726A 165 110 149 107 CAGGTCGAGCTGCGAT 185 194 209
72-01A (IrJ) V726A 165 110 149 107 CAGGTCGAGCTGCGAT 185 194 209
146-19A (Arab) V726A 165 98 149 107 CAGGTCGAGCTGCGAT 185 194 209
32-08A (AJ) V726A 165 110 149 101 CAGGTCGAGCTGCGAT 185 194/200 215
K.X. (AJ) V726A/V726A 165/185 110/98 149/141 101/101 CAGGTCGAGCTGCGAT 185/185 194/194 215/215
T.M. (AJ) V726A/V726A 165/193 110/94 149/153 101/101 CAGGTCGAGCTGCGAT 185/185 194/194 215/213
Sicilian M694V 165 118 153 104 TGGACTAGACCAAGGC nd 184 nd
Sicilian M680I 165 118 149 110 TACGTCGAGCTGAGGC nd 186 nd
a Dr  Druze, AJ  Ashkenazi Jewish, and IrJ  Iraqi Jewish. Pedigree 43 is shown in figure 2; the Sicilian family is shown in figure 3.
b The order of the genetic markers in the table is the same as the order on the chromosome, withD16S3405 the most telomeric andD16S3376
the most centromeric. Underlined alleles represent a putative haplotype, determined on the basis of allele similarities with other knownhaplotypes.
nd  not done.
c The order of intragenic polymorphisms is as follows: tel-3′-nt 2177 (amino acid [aa] 726)-nt 2080 (aa 694)-nt2040 (aa 680)-nt 1764 (x9.1)-
nt 161095 (i6.1)-nt 1530 (x5.3)-nt 1428 (x5.2)-nt 1422 (x5.1)-nt 135643 (i4.1)-nt 1105 (aa 369)-nt 942 (x3.1)-nt 605 (x2.4)-nt 495 (x2.3)-
nt 442 (aa 148)-nt 414 (x2.2)-nt 306 (x2.1). Underlined sites are locations of mutations, with mutant alleles in boldface type.
accounting for an additional 20%. It is noteworthy that
E148Q was present on only 9 (25%) of 36 carrier chro-
mosomes in Ashkenazi patients with FMF, whereas
P369S was present in 3 (8%) of 36. Consistent with the
hypothesis that E148Q and P369S are not fully pene-
trant in the Ashkenazi population, we identified one
E148Q homozygote and one P369S homozygote from
the screening panel of 200 asymptomatic individuals.
The K695R mutation was also overrepresented in the
general Ashkenazi sample, accounting for 12% of the
carrier chromosomes, but was only observed on 2 (5%)
of 36 Ashkenazi FMF patient chromosomes.
In contrast, the M694V and V726A mutations ac-
counted for higher percentages of FMF patient chro-
mosomes than would be expected from their relative
frequencies in the overall Ashkenazi population. We ob-
served M694V in 3 of 36 patient chromosomes but in
none of 420 anonymous Ashkenazi chromosomes. Sim-
ilarly, V726A was present in 17 ( 47%) of 36 of the
Ashkenazi patients’ chromosomes but comprised only
18% of the carrier chromosomes in the unselected Ash-
kenazi panel.
On the basis of low population-based estimates of the
Ashkenazi Jewish carrier frequency, Yuval et al. (1995)
suggested that an Ashkenazi family exhibiting four-gen-
eration inheritance of FMF might be because of a rare
dominant mode of transmission in this family. The
higher Ashkenazi carrier frequencies measured in the
present study increase the possibility that asymptomatic
carriers married into this family; therefore, DNA spec-
imens were obtained from the family to test this hy-
pothesis. The results are shown in figure 2. In both mar-
riages in which it was at issue, there was evidence that
asymptomatic carriers married into the family. Thus, the
mother of 43-01 and 43-02 can be inferred to be a carrier
for E148Q, and 43-04 is a carrier for V726A.
Haplotype analysis, presented in figure 2 and table 3,
indicates that Ashkenazi Jewish FMF carrier chromo-
somes share common ancestors with carriers from other
ethnic groups. For example, in figure 2, the E148Q-
V726A complex allele is found on a microsatellite hap-
lotype designated as the “C” (International FMF Con-
sortium 1997) or “Arm3” (French FMF Consortium
1997) haplotype, which has been observed in several
ethnic groups. As noted previously, Ashkenazi E148Q-
bearing chromosomes share a common ancestral SNP
haplotype with other chromosomes bearing this muta-
tion. Table 3 also illustrates common SNP and micro-
satellite genotypes in V726A-bearing chromosomes of
Ashkenazi Jewish, Iraqi Jewish, and Arab descent.
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Table 4
MEFV Mutation Frequencies in the U.S. Ashkenazi Jewish Population
Mutation
No. of Chromosomes
Positive
No. of Chromosomes
Scored Gene Frequency Carrier Frequencya
E148Q 23 420 .055 .104
E167D 0 172 .000 .000
P369S 10 426 .023 .045
M680Ib/M680Ic 0 225 .000 .000
M694V 0 420 .000 .000
M694I 0 122 .000 .000
K695R 6 402 .015 .030
V726A 9 400 .022 .043
A744S 1 146 .007 .014
R761H 0 105 .000 .000
Total 49 ∼400 .122 .214
a Calculated as twice the gene frequency times (1 minus the gene frequency). The total carrier frequency was
calculated from applying this formula to the sum of the observed gene frequencies.
b 2040GrC.
c 2040GrA.
FMF in Patients of Italian Ancestry
Table 2 presents mutation data on 14 unrelated FMF
patients of Italian ancestry. The E148Q mutation was
observed without P369S or V726A in seven carrier chro-
mosomes and as the E148Q-V726A complex allele once.
Haplotype analysis in a Sicilian family segregating the
E148Q mutation is shown in table 3 and figure 3. With
the exception of a probable “slippage” mutation at
D16S3404, the microsatellite and SNP haplotype asso-
ciated with E148Q in this family was identical to that
found in an Israeli Arab family (146), from D16S3275
to at least D16S3405. In another patient of Italian an-
cestry, we observed the M694I mutation, which also
occurs primarily in Arabs (table 2; French FMF Con-
sortium, 1997).
The M694V mutation was seen in a total of six un-
related Italian carrier chromosomes, including one in the
aforementioned Sicilian family. Haplotype analysis in
this family (fig. 3) places this mutation on the A “(Med)”
haplotype, the major founder chromosome associated
with M694V in several Mediterranean populations. The
third mutation segregating in this family, M680I, is also
seen in patients of Armenian and Turkish ancestry. The
M680I Sicilian haplotype appears to be the same as one
previously found in the Armenian population, desig-
nated either as the “K” haplotype (International FMF
Consortium 1997) or the “Arm2” haplotype (French
FMF Consortium 1997). The area of identity extends at
least from D16S3405 (fig. 3) through the intragenic
SNPs (data not shown), with the exception of a probable
“slippage” mutation at D16S2617.
Discussion
The present report adds substantially to an emerging
body of data indicating a much more complex muta-
tional picture in FMF than had been appreciated with
the initial cloning of MEFV. Whereas four mutations in
a single exon accounted for a large percentage of the
mostly North African Jewish carrier chromosomes in the
first reports (French FMF Consortium 1997; Interna-
tional FMF Consortium 1997), our present data from a
more diverse sample indicate a larger pool of disease-
associated mutations that are not restricted to a single
domain of the pyrin/marenostrin protein, with the pros-
pect that there are yet more mutations to be found.
Moreover, in performing the first reported population-
based MEFV mutational screen, we have obtained evi-
dence for relatively common mutations with reduced
penetrance among Ashkenazi Jews, thus blurring the dis-
tinction between MEFV mutations and polymorphisms.
Finally, the SNP and microsatellite haplotype data pre-
sented here suggest intriguing ancestral relationships
among FMF carrier chromosomes.
Table 5 summarizes the 16MEFVmutations identified
at the time of this writing, two of which are described
for the first time in this report. For each mutation, we
have listed the combined experience from our own lab-
oratories and the French FMF Consortium, with regard
to gene frequencies in panels of DNA samples repre-
senting the general North American/northern European
population and among chromosomes identified by seg-
regation analysis as being noncarriers for FMF. For 13
of the 16 mutations, no positives were found in an ag-
gregate experience of as many as several hundred control
chromosomes. It is interesting to note that the three mu-
tations that were detected at low frequency among the
control panels (E148Q, P369S, and K695R) were rela-
tively common in our Ashkenazi Jewish sample. The
positives in the general population therefore may be car-
riers with partial ancestry from one of the high-risk eth-
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Figure 2 Pedigree of an Ashkenazi Jewish family previously thought to exhibit dominant inheritance of FMF. The diagram is adapted
from the report by Yuval et al. (1995). Microsatellite typings are listed from telomere (top) to centromere (bottom), withMEFV residing between
D16S2617 and D16S3275. Affected individuals in the first two generations were not available for genotyping. In the report by Yuval et al.
(1995), individual 43-03 was explained as a nonpenetrant carrier of a dominant mutation.
nic groups. Table 1 and figure 1 also present rapid-
screening assays for the two novel mutations described
here, as well as for five other recently published
mutations.
Eleven of the 16 mutations listed in table 5 are located
in exon 10 and would be predicted to affect the B30.2
ret finger protein C-terminal domain of pyrin. E148Q
and E167D are not part of any recognizable motif or
domain in the protein (International FMF Consortium
1997), but T267I falls within the bZIP basic domain,
P369S is 6 amino acids N-terminal to the B-box zinc
finger domain, and F479L resides within the a-helical
(coiled-coil) domain. As yet, no MEFV mutation has
been identified in FMF that would be predicted to trun-
cate the pyrin protein; thus, the data continue to be
consistent with the hypothesis that more profound loss-
of-function mutations may lead to a different phenotype
(International FMF Consortium 1997).
Our ability to account for only 79% of the carrier
chromosomes of the patients presented in table 2 sets
an approximate upper limit to the sensitivity of current
site-specific testing for the identification of MEFV mu-
tations. Because we sequenced exon 10 for all these pa-
tients, our survey would only miss T267I and F479L,
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Figure 3 Haplotype analysis of a Sicilian family with FMF. Microsatellite marker order is the same as in figure 2. Three differentMEFV
mutations, with associated haplotypes, segregated in this family. The haplotype with the M694V mutation has been observed in several
Mediterranean populations; the haplotypes associated with E148Q and M680I have been observed in Arab and Armenian families, respectively.
Individual III-2 is age 13 years and has experienced no symptoms of FMF to date.
which are reportedly infrequent mutations (Bernot et al.
1998). Conversely, the sensitivity could be somewhat
lower if there are patients with FMF for whom we have
not yet detected mutations on either chromosome. Our
clinical analysis of 100 American periodic fever referrals
indicates that such patients probably exist (Samuels et
al. 1998), although it is difficult to estimate their number
in the present series, since complete clinical data were
not available for each of the samples received. Assuming
that the current screening assays identify only ∼75% of
FMF carrier chromosomes, then 6% ( ) of0.25 # 0.25
patients with FMF would be predicted to be completely
negative for these assays. It is possible that these patients
may have mutations in regions of MEFV that were not
screened or that their periodic illness is caused by an-
other locus (Akarsu et al. 1997).
Perhaps the most interesting and provocative finding
of this report is the demonstration, by direct mutational
screening in a panel of unselected DNA samples, of an
FMF carrier frequency of ∼1/5 in the Ashkenazi Jewish
population. Previous estimates of the FMF gene and car-
rier frequency in this ethnic group have been lower and
were inferred from enumerations of symptomatic indi-
viduals either in the Israeli population (Yuval et al. 1995)
or in Ashkenazi families with FMF (Daniels et al. 1995).
There is no evidence to suggest that the Ashkenazi Jewish
population of the United States differs substantially from
that of Israel, and the allele frequencies for several ge-
netic disorders determined from the New York Univer-
sity Ashkenazi population are consistent with those of
other studies of Ashkenazi Jews (Kronn et al. 1998; H.
Ostrer, unpublished data). None of these individuals
gave any history of symptoms compatible with FMF.
Against the possibility that there was a significant degree
of unrecognized Sephardi Jewish ancestry among our
panel, the M694V MEFV mutation was not detected.
Another way of reconciling our Ashkenazi frequency
data with previous estimates would be to propose that
at least some of the putative mutations tested here are
actually population-specific polymorphisms in linkage
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Table 5
Summary of MEFV Mutations
NUCLEOTIDE
AMINO
ACID
EXON
CONTROL CHROMOSOMES
REFERENCE
Present Study
French FMF
Consortium
North American NCa CEPH NCa
442GrC E148Q 2 1/206 0/40 1/148 2/131 Present study; Bernot et al. (1998)
501GrC E167D 2 0/94 0/26 0/148 0/57 Present study; Bernot et al. (1998)
800CrA T267I 2 ) ) 0/148 0/57 Bernot et al. (1998)
1105CrT P369S 3 1/222 ) ) ) Present study
1437CrG F479L 5 ) ) 0/120 0/51 Bernot et al. (1998)
2040GrC M680I 10 0/222 0/105 0/146 0/1250 International FMF Consortium (1997);
French FMF Consortium (1997)
2040GrA M680I 10 0/222 0/105 ) ) Present study
2042CrT T681I 10 0/190 0/105 ) ) Booth et al. (1998)
2076-2078del I692del 10 0/190 0/105 0/146 0/52 Bernot et al.(1998)
2078-2080del M694del 10 0/190 0/105 ) ) Booth et al. (1998)
2080ArG M694V 10 0/190 0/105 0/146 0/1250 International FMF Consortium (1997);
French FMF Consortium (1997)
2082GrA M694I 10 0/190 0/105 0/146 0/1250 French FMF Consortium (1997)
2084ArG K695R 10 0/190 0/105 0/146 1/52 Present study; Bernot et al. (1998)
2177TrC V726A 10 0/178 0/105 0/146 0/1250 International FMF Consortium (1997);
French FMF Consortium (1997)
2230GrT A744S 10 0/140 ) 0/146 0/52 Present study; Bernot et al. (1998)
2282GrA R761H 10 0/137 ) 0/146 0/52 Present study; Bernot et al. (1998)
a Noncarrier chromosomes (NC), as determined by segregation analysis in FMF families.
disequilibrium with “real” mutations elsewhere in
MEFV. By this hypothesis, perhaps only a small fraction
of the chromosomes bearing E148Q, for instance, might
have the associated bona fide mutation. If, in table 4,
we were to consider only the observed frequency of
V726A to estimate the FMF carrier frequency in the
Ashkenazi population, the resulting figure of 1/23 would
fall within the range of previous estimates (1/135–1/11),
although definitely on the high end of the range. More-
over, it could be argued that there are already a sub-
stantial number of other known sequence variants
within the coding region of MEFV that definitely are
polymorphisms (determined on the basis of the frequent
observation of both variants in haplotype-proven non-
carrier chromosomes). In our original positional cloning
paper, we identified nine of these polymorphic sequence
variants, all but one being third base, synonymous sub-
stitutions: D102 (x2.1), G138 (x2.2), A165 (x2.3),
R202Q (x2.4), R314 (x3.1), E474 (x5.1), Q476 (x5.2),
D510 (x5.3), and P588 (x9.1). Bernot et al. (1998) have
subsequently identified four additional silent substitu-
tions: Y65, P393, S683, and P706.
It is, however, important to point out the differences
between the putative mutations found at high frequency
in the Ashkenazi population and the aforementioned
polymorphisms. The two most frequent substitutions,
glutamine for glutamic acid (E148Q) and serine for pro-
line (P369S), could readily lead to conformational
changes in the pyrin protein; K695R and A744S would
be predicted to cause more subtle changes but reside
within a domain already known to be sensitive to rel-
atively conservative amino acid substitutions.Moreover,
for each of these putative mutations, we have sequenced
the entire coding region and splice junctions of MEFV
without finding other substitutions (except in the case
of the complex alleles described). Bernot et al. (1998)
performed similar analyses of E148Q, E167D, T267I,
and F479L. It is unlikely, on the basis of these arguments,
that the variants screened in the Ashkenazi population
are polymorphisms in linkage disequilibrium with as yet
unknown true mutations.
Instead, the variants presented in table 4 are likely to
be mutations, with several exhibiting relatively low pen-
etrance. Reduced penetrance in women has long been
invoked to explain the 1.5–2:1 male-to-female ratio in
FMF, but the discordance between gene frequencies in-
ferred from symptomatic cases and those determined by
molecular analysis suggest a quantitatively more sub-
stantial effect among the Ashkenazim. On the basis of
the disproportion among the frequencies of E148Q,
P369S, and K695R in the general Ashkenazi population
and among Ashkenazi FMF carrier chromosomes, it is
likely that these three mutations are not fully penetrant
in this population. Moreover, we directly observed
E148Q and P369S homozygotes among the asympto-
matic Ashkenazi screening panel. This latter observation
emphasizes the need for caution in making the diagnosis
of FMF on the basis of DNA testing alone and indicates
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the importance of similar mutational screens in other
Mediterranean populations. Available data suggest that
M694V is highly penetrant in the North African Jewish
population (French FMF Consortium 1997; Interna-
tional FMF Consortium 1997).
The concept of reduced penetrance among Ashkenazi
Jews is consistent with clinical studies suggesting that
this population may have somewhat milder disease than
Sephardi Jews, with a much lower incidence of amyloi-
dosis (Pras et al. 1982). Several Ashkenazi patients in
our mutation panel have relatively mild disease: one
K695R/(E148Q-V726A) heterozygote experienced a 30-
year spontaneous remission when not taking colchicine;
a E148Q/(E148Q-P369S) heterozygote experienced typ-
ical attacks as a child but has been attack-free without
colchicine for 20 years, as an adult; and another V726A/
(E148Q-V726A) compound heterozygote has been at-
tack-free for 20 years while taking colchicine. The dis-
order in the first two patients could have easily escaped
diagnosis. The present data do not exclude the possibility
that part of the reduction in penetrance and severity of
disease could be because of non-MEFV modifier genes
or environmental factors in the Ashkenazi population.
Alternatively, reduced penetrance may be a property of
certain of the more frequent mutations in the Ashke-
nazim, such as E148Q.
SNP haplotype data presented in this report suggest
that chromosomes bearing E148Q from several ethnic
groups probably share a common progenitor, thus im-
plicating a founder effect. Bernot et al. (1998) defined
several microsatellite haplotypes associated with E148Q
in their study population. A novel founder haplotype,
designated “S2,” was observed only among North Af-
rican Jewish carriers of the E148Q mutation. The au-
thors concluded that E148Q is a recurrent mutation, on
the basis of the observation of other distinct microsat-
ellite haplotypes, although six of the seven independent
E148Q FMF chromosomes reported in their article had
the same SNP motif presented here. The fact that these
haplotypes only converge at the level of intragenic SNPs
suggests a relatively ancient founder. Together with the
previous intragenic SNP haplotype analysis of the
M694V and M680I mutations (International FMF Con-
sortium 1997), our E148Q data underscore the utility
of these relatively stable polymorphisms in studying very
old mutations. A hypothetical E148Q progenitor com-
mon to all the populations harboring this mutation
would most likely have lived 1,500–2,000 years ago
(Goodman 1979).
Other haplotype data fromAshkenazi and Italian fam-
ilies in the present report also support the view thatmany
FMF carrier chromosomes from disparate ethnic groups
are descended from a limited number of ancestral chro-
mosomes. Apparent ancestral ties between Sicilian and
Arab, Jewish, and Armenian FMF carriers are especially
noteworthy and probably reflect Sicily’s historic status
as a crossroads of Mediterranean commerce.
Nevertheless, the high frequency of several mutations
in different populations of Mediterranean descent sug-
gests a role for evolutionary selection. Demonstrating
the precise nature of an FMF selective advantage may
not be easy, given that antibiotic therapy and modern
public health measures are likely to obscure the effects
of infectious diseases and that even a small advantage
compounded over many generations may give rise to a
high carrier frequency. One recent study (Brenner-Ull-
man et al. 1994) proposed a reduced rate of asthma in
obligate FMF heterozygotes, but the differences between
groups was of borderline statistical significance. Animal
models currently under development may contribute
substantially to the resolution of these issues.
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